Artelo Biosciences Advances ART27.13 with Patent Allowance
Key Development for Artelo Biosciences
Artelo Biosciences, Inc., a pioneering pharmaceutical company focused on innovative therapeutic solutions, recently garnered significant recognition as it received a Notice of Allowance from the European Patent Office (EPO). This approval is associated with their European patent application No. 21827629.3, targeting the intended commercial formulation of ART27.13.
The Importance of Patent Protection
This patent covers crucial compositions of ART27.13, which is currently being evaluated as a therapeutic option for cancer-related anorexia. By extending patent protection, potentially through December 2041, Artelo is enhancing its intellectual property strategy, ensuring the long-term viability and commercial potential of ART27.13.
Addressing Cancer-Related Anorexia
ART27.13 is designed to tackle the challenges of cancer-related anorexia, a condition impacting over 60% of advanced-stage cancer patients. Notably, there are currently no approved treatments in regions like the US and EU for this condition. CEO Gregory D. Gorgas emphasized the potential of ART27.13 to offer a first-in-class solution tailored for these patients.
Clinical Trials and Evaluation
The drug is under evaluation in the Phase 2 CAReS clinical trial, examining its effectiveness in reversing weight loss among cancer patients. Preliminary results from previous studies indicate that the drug was well tolerated and showed strength in stabilizing or reversing weight loss in a notable portion of participants. The Phase 2 results are expected to unveil during the third quarter of 2025.
The Science Behind ART27.13
Developed originally by AstraZeneca, ART27.13 is a groundbreaking benzimidazole derivative, administered orally once daily. It selectively targets peripheral cannabinoid receptors CB1 and CB2, with promising applications in improving appetite and combating muscle degeneration, ultimately enhancing the quality of life for cancer patients.
Clinical Findings and Future Potential
Over 250 participants have already been involved in six clinical studies, where ART27.13 has demonstrated its ability to significantly improve body weight among healthy individuals with back pain. Importantly, ART27.13 aims to achieve systemic metabolic benefits while minimizing adverse effects typically associated with central nervous system interactions.
Understanding the CAReS Study
The Cancer Appetite Recovery Study (CAReS) is pivotal for exploring ART27.13's potential as a treatment for those suffering from cancer-related weight loss. The study is structured to assess the drug’s effectiveness in increasing lean body mass and appetite—integral factors in enhancing patient recovery and comfort during cancer treatment.
Challenges of Cancer-Related Anorexia
Patients dealing with cancer often face the distressing issue of anorexia, leading to adverse health outcomes and weakened immunity. A weight loss exceeding 5% in these patients can be indicative of poor prognoses, stressing the need for effective interventions like ART27.13.
About Artelo Biosciences
Artelo Biosciences is dedicated to developing therapeutics that modulate lipid-signaling pathways, aiming to meet significant clinical needs across various conditions such as cancer, anxiety, and chronic pain. Alongside its therapeutic efforts, the company is innovating in finance by designating Solana as a core reserve asset, leveraging blockchain technology to diversify its financial strategies and enhance shareholder value.
Contact Information
For further inquiries, please reach out to Crescendo Communications, LLC, at 212-671-1020 or via email at ARTL@crescendo-ir.com.
Frequently Asked Questions
What is the focus of Artelo Biosciences?
Artelo Biosciences focuses on developing therapeutics that modulate lipid-signaling pathways for conditions like cancer and pain management.
What is ART27.13?
ART27.13 is a cannabinoid agonist being evaluated as a treatment for cancer-related anorexia.
Why is the patent allowance important?
The patent allowance secures the commercial potential of ART27.13 and protects the formulation against competition.
What is the CAReS clinical trial?
The CAReS clinical trial is a Phase 1/2 study evaluating the efficacy of ART27.13 in patients suffering from cancer-related anorexia.
How can I stay updated on Artelo’s progress?
Stay informed by visiting Artelo’s official website or following their announcements on their social media platforms.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.